image
Healthcare - Medical - Care Facilities - NYSE - US
$ 1.58
-7.6 %
$ 651 M
Market Cap
-2.08
P/E
1. INTRINSIC VALUE

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.[ Read More ]

The intrinsic value of one AGL stock under the base case scenario is HIDDEN Compared to the current market price of 1.58 USD, agilon health, inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AGL

image
FINANCIALS
4.32 B REVENUE
59.38%
-232 M OPERATING INCOME
-110.62%
-263 M NET INCOME
-145.92%
-156 M OPERATING CASH FLOW
-19.41%
-44 M INVESTING CASH FLOW
90.09%
-193 M FINANCING CASH FLOW
-688.38%
1.45 B REVENUE
-2.15%
-134 M OPERATING INCOME
-214.31%
-127 M NET INCOME
-313.42%
-7.7 M OPERATING CASH FLOW
58.84%
46.6 M INVESTING CASH FLOW
155.60%
-1.41 M FINANCING CASH FLOW
17.97%
Balance Sheet Decomposition agilon health, inc.
image
Current Assets 1.48 B
Cash & Short-Term Investments 488 M
Receivables 942 M
Other Current Assets 49.3 M
Non-Current Assets 261 M
Long-Term Investments 44.8 M
PP&E 41 M
Other Non-Current Assets 175 M
Current Liabilities 977 M
Accounts Payable 968 M
Short-Term Debt 9.1 M
Other Current Liabilities 0
Non-Current Liabilities 103 M
Long-Term Debt 43.2 M
Other Non-Current Liabilities 59.5 M
EFFICIENCY
Earnings Waterfall agilon health, inc.
image
Revenue 4.32 B
Cost Of Revenue 4.25 B
Gross Profit 69.7 M
Operating Expenses 302 M
Operating Income -232 M
Other Expenses 30.7 M
Net Income -263 M
RATIOS
1.61% GROSS MARGIN
1.61%
-5.38% OPERATING MARGIN
-5.38%
-6.08% NET MARGIN
-6.08%
-39.68% ROE
-39.68%
-15.08% ROA
-15.08%
-33.28% ROIC
-33.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis agilon health, inc.
image
Net Income -263 M
Depreciation & Amortization 20.2 M
Capital Expenditures -30.8 M
Stock-Based Compensation 69.5 M
Change in Working Capital -10.1 M
Others -457 M
Free Cash Flow -187 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets agilon health, inc.
image
Wall Street analysts predict an average 1-year price target for AGL of $4.4 , with forecasts ranging from a low of $2.5 to a high of $6.5 .
AGL Lowest Price Target Wall Street Target
2.5 USD 58.23%
AGL Average Price Target Wall Street Target
4.4 USD 178.48%
AGL Highest Price Target Wall Street Target
6.5 USD 311.39%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.45 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership agilon health, inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
67.2 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 5
6-9 MONTHS
250 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 12, 2024
Bought 67.2 K USD
Sell Steven
CEO & President
+ 20000
3.3594 USD
8 months ago
Mar 14, 2024
Bought 0 USD
Kornitzer Benjamin
Chief Med. & Quality Officer
+ 5434
0 USD
8 months ago
Mar 14, 2024
Bought 0 USD
Venkatachaliah Girish
Chief Technology Officer
+ 5434
0 USD
8 months ago
Mar 14, 2024
Bought 0 USD
Shaker Benjamin
Chief Markets Officer
+ 274455
0 USD
8 months ago
Mar 14, 2024
Bought 0 USD
Desai Veeral
Chief Strategy & Dev. Officer
+ 11956
0 USD
8 months ago
Mar 14, 2024
Bought 0 USD
Bensley Timothy
Chief Financial Officer
+ 14945
0 USD
11 months ago
Nov 29, 2023
Bought 250 K USD
Schwaneke Jeffrey A.
Director
+ 22300
11.22 USD
1 year ago
Sep 12, 2023
Sell 338 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
18.0523 USD
1 year ago
Sep 13, 2023
Sell 337 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
17.9976 USD
1 year ago
Sep 11, 2023
Sell 326 K USD
Gertsch Timothy
Chief Accounting Officer
- 17500
18.6159 USD
1 year ago
Sep 11, 2023
Sell 163 K USD
Gertsch Timothy
Chief Accounting Officer
- 8750
18.61 USD
1 year ago
Aug 14, 2023
Sell 351 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
18.7244 USD
1 year ago
Aug 15, 2023
Sell 339 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
18.0965 USD
1 year ago
Jul 12, 2023
Sell 318 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
16.9697 USD
1 year ago
Jul 13, 2023
Sell 317 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
16.9293 USD
1 year ago
Jun 14, 2023
Sell 21.1 K USD
Shaker Benjamin
Chief Markets Officer
- 1100
19.1676 USD
1 year ago
Jun 14, 2023
Sell 33.2 K USD
Shaker Benjamin
Chief Markets Officer
- 1851
17.9328 USD
1 year ago
Jun 14, 2023
Sell 294 K USD
Shaker Benjamin
Chief Markets Officer
- 15799
18.6004 USD
1 year ago
Jun 15, 2023
Sell 351 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
18.7255 USD
1 year ago
May 18, 2023
Sell 1.96 B USD
CD&R Investment Associates IX, Ltd.
10 percent owner
- 94173804
20.8013 USD
1 year ago
May 15, 2023
Sell 595 K USD
Shaker Benjamin
Chief Markets Officer
- 25000
23.7893 USD
1 year ago
May 16, 2023
Sell 579 K USD
Shaker Benjamin
Chief Markets Officer
- 25000
23.1414 USD
1 year ago
May 09, 2023
Sell 118 K USD
Desai Veeral
Chief Strategy & Dev. Officer
- 4500
26.1479 USD
1 year ago
Apr 19, 2023
Sell 122 K USD
Desai Veeral
Chief Strategy & Dev. Officer
- 4545
26.8157 USD
1 year ago
Apr 20, 2023
Sell 13.1 K USD
Desai Veeral
Chief Strategy & Dev. Officer
- 500
26.148 USD
1 year ago
Apr 19, 2023
Sell 12.7 K USD
Desai Veeral
Chief Strategy & Dev. Officer
- 455
27.8382 USD
1 year ago
Apr 17, 2023
Sell 654 K USD
Shaker Benjamin
Chief Markets Officer
- 23600
27.6966 USD
1 year ago
Apr 18, 2023
Sell 701 K USD
Shaker Benjamin
Chief Markets Officer
- 25000
28.0452 USD
1 year ago
Apr 17, 2023
Sell 40 K USD
Shaker Benjamin
Chief Markets Officer
- 1400
28.5407 USD
1 year ago
Mar 24, 2023
Sell 2.79 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 97290
28.7016 USD
1 year ago
Mar 23, 2023
Sell 652 K USD
Desai Veeral
Chief Strategy & Dev. Officer
- 22710
28.7059 USD
1 year ago
Mar 23, 2023
Sell 227 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
28.0428 USD
1 year ago
Mar 22, 2023
Sell 225 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
27.8448 USD
1 year ago
Mar 15, 2023
Sell 1.91 M USD
Wulf John William
Director
- 80000
23.8153 USD
1 year ago
Mar 15, 2023
Sell 833 K USD
Shaker Benjamin
Chief Markets Officer
- 35000
23.8066 USD
1 year ago
Mar 16, 2023
Sell 112 K USD
Shaker Benjamin
Chief Markets Officer
- 4588
24.3551 USD
1 year ago
Mar 16, 2023
Sell 252 K USD
Shaker Benjamin
Chief Markets Officer
- 9831
25.6527 USD
1 year ago
Mar 16, 2023
Sell 276 K USD
Shaker Benjamin
Chief Markets Officer
- 10581
26.0812 USD
1 year ago
Mar 15, 2023
Sell 595 K USD
Shaker Benjamin
Chief Markets Officer
- 25000
23.803 USD
1 year ago
Mar 15, 2023
Sell 1.31 M USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 55000
23.8077 USD
1 year ago
Mar 16, 2023
Sell 1.57 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 60000
26.0866 USD
1 year ago
Mar 08, 2023
Sell 198 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
24.4404 USD
1 year ago
Mar 07, 2023
Sell 197 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
24.3634 USD
1 year ago
Feb 15, 2023
Sell 667 K USD
Shaker Benjamin
Chief Markets Officer
- 28555
23.3704 USD
1 year ago
Feb 14, 2023
Sell 1.15 M USD
Shaker Benjamin
Chief Markets Officer
- 50000
22.9812 USD
1 year ago
Feb 15, 2023
Sell 186 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
22.9834 USD
1 year ago
Feb 14, 2023
Sell 595 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 25881
22.9851 USD
1 year ago
Feb 02, 2023
Sell 708 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 30782
22.9862 USD
1 year ago
Feb 01, 2023
Sell 117 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
21.7605 USD
1 year ago
Jan 20, 2023
Sell 107 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
19.9214 USD
1 year ago
Jan 18, 2023
Sell 410 K USD
Shaker Benjamin
Chief Markets Officer
- 20723
19.7794 USD
1 year ago
Jan 06, 2023
Sell 41.7 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 2698
15.4565 USD
1 year ago
Dec 16, 2022
Sell 90.8 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5398
16.8224 USD
1 year ago
Dec 15, 2022
Sell 324 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
17.262 USD
1 year ago
Dec 06, 2022
Sell 95.6 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5398
17.7161 USD
2 years ago
Nov 18, 2022
Bought 49.7 K USD
Sell Steven
CEO & President
+ 2900
17.1395 USD
2 years ago
Nov 16, 2022
Sell 343 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
18.2938 USD
2 years ago
Nov 17, 2022
Sell 322 K USD
Shaker Benjamin
Chief Markets Officer
- 18750
17.171 USD
2 years ago
Nov 16, 2022
Sell 99.9 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
18.5172 USD
2 years ago
Nov 17, 2022
Sell 94.1 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
17.4305 USD
2 years ago
Nov 02, 2022
Sell 105 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
19.5343 USD
2 years ago
Oct 20, 2022
Sell 571 K USD
Shaker Benjamin
Chief Markets Officer
- 28048
20.3524 USD
2 years ago
Oct 19, 2022
Sell 388 K USD
Shaker Benjamin
Chief Markets Officer
- 19552
19.8403 USD
2 years ago
Oct 20, 2022
Sell 31 K USD
Shaker Benjamin
Chief Markets Officer
- 1500
20.6607 USD
2 years ago
Oct 20, 2022
Sell 571 K USD
Shaker Benjamin
Chief Markets Officer
- 28048
20.3524 USD
2 years ago
Oct 19, 2022
Sell 388 K USD
Shaker Benjamin
Chief Markets Officer
- 19552
19.8403 USD
2 years ago
Oct 20, 2022
Sell 31 K USD
Shaker Benjamin
Chief Markets Officer
- 1500
20.6607 USD
2 years ago
Oct 17, 2022
Sell 118 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
21.7898 USD
2 years ago
Oct 03, 2022
Sell 188 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
23.1657 USD
2 years ago
Sep 26, 2022
Sell 122 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
22.6227 USD
2 years ago
Sep 27, 2022
Sell 248 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 10792
22.9773 USD
2 years ago
Sep 08, 2022
Sell 238 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 10546
22.558 USD
2 years ago
Sep 09, 2022
Sell 187 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
23.0777 USD
2 years ago
Sep 08, 2022
Sell 67.8 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 2944
23.0229 USD
2 years ago
Aug 23, 2022
Sell 111 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
20.4879 USD
2 years ago
Aug 11, 2022
Sell 276 M USD
CD&R Vector Holdings, L.P.
director:
- 11337500
24.35 USD
2 years ago
Aug 11, 2022
Sell 276 M USD
CD&R Investment Associates IX, Ltd.
10 percent owner
- 11337500
24.35 USD
2 years ago
Aug 04, 2022
Sell 211 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
26.0866 USD
2 years ago
Jul 21, 2022
Sell 2.19 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 79768
27.5 USD
2 years ago
Jul 20, 2022
Sell 1.08 M USD
Shaker Benjamin
Chief Markets Officer
- 39052
27.6257 USD
2 years ago
Jul 15, 2022
Sell 215 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 8094
26.574 USD
2 years ago
Jul 07, 2022
Sell 7.98 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 319071
25 USD
2 years ago
Jul 01, 2022
Sell 826 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 35791
23.0664 USD
2 years ago
Jun 24, 2022
Sell 2.39 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 106357
22.5 USD
2 years ago
Jun 22, 2022
Sell 107 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
19.8769 USD
2 years ago
Jun 09, 2022
Sell 104 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
19.3284 USD
2 years ago
May 27, 2022
Sell 107 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
19.77 USD
2 years ago
May 25, 2022
Sell 2.85 M USD
SMITH MICHAEL L
director:
- 145874
19.5337 USD
2 years ago
May 10, 2022
Sell 86.1 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
15.9507 USD
2 years ago
Apr 27, 2022
Sell 98.7 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 5396
18.2981 USD
2 years ago
Apr 21, 2022
Sell 536 K USD
Desai Veeral
Chief Strategy & Dev. Officer
- 26789
20 USD
2 years ago
Apr 19, 2022
Sell 2.38 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 106357
22.34 USD
2 years ago
Apr 18, 2022
Sell 139 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 6296
22.14 USD
2 years ago
Apr 07, 2022
Sell 67.7 K USD
Shaker Benjamin
Chief Markets Officer
- 2706
25.01 USD
2 years ago
Mar 16, 2022
Sell 4.03 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 197291
20.41 USD
2 years ago
Mar 16, 2022
Sell 751 K USD
Shaker Benjamin
Chief Markets Officer
- 37155
20.2 USD
2 years ago
Mar 15, 2022
Sell 212 K USD
Wulf John William
director:
- 11100
19.13 USD
2 years ago
Mar 14, 2022
Sell 325 K USD
Shaker Benjamin
Chief Markets Officer
- 15760
20.6 USD
2 years ago
Dec 31, 2021
Sell 32 K USD
Halkias Theodore
Chief Business Officer
- 1162
27.55 USD
2 years ago
Dec 30, 2021
Sell 334 K USD
Halkias Theodore
Chief Business Officer
- 12113
27.54 USD
2 years ago
Dec 28, 2021
Sell 376 K USD
Shaker Benjamin
Chief Markets Officer
- 14055
26.72 USD
2 years ago
Dec 29, 2021
Sell 124 K USD
Shaker Benjamin
Chief Markets Officer
- 4685
26.54 USD
2 years ago
Dec 27, 2021
Sell 154 K USD
Halkias Theodore
Chief Business Officer
- 5583
27.53 USD
2 years ago
Dec 23, 2021
Sell 582 K USD
Halkias Theodore
Chief Business Officer
- 21142
27.52 USD
2 years ago
Dec 17, 2021
Sell 64.3 K USD
Danieley Joan
Chief Administrative Officer
- 2888
22.27 USD
2 years ago
Dec 17, 2021
Sell 427 K USD
Danieley Joan
Chief Administrative Officer
- 18593
22.97 USD
2 years ago
Dec 15, 2021
Sell 346 K USD
Danieley Joan
Chief Administrative Officer
- 15321
22.58 USD
2 years ago
Dec 15, 2021
Sell 225 K USD
Danieley Joan
Chief Administrative Officer
- 9679
23.29 USD
2 years ago
Dec 16, 2021
Sell 81.4 K USD
Danieley Joan
Chief Administrative Officer
- 3519
23.14 USD
3 years ago
Nov 16, 2021
Sell 119 K USD
Shaker Benjamin
Chief Markets Officer
- 4685
25.37 USD
3 years ago
Nov 17, 2021
Sell 118 K USD
Shaker Benjamin
Chief Markets Officer
- 4685
25.26 USD
3 years ago
Nov 04, 2021
Sell 3.78 M USD
Sobotka Glenn
Chief Accounting Officer
- 150000
25.19 USD
3 years ago
Nov 04, 2021
Sell 468 K USD
Shaker Benjamin
Chief Markets Officer
- 18560
25.19 USD
3 years ago
Nov 03, 2021
Sell 7.5 K USD
Shaker Benjamin
Chief Markets Officer
- 300
25 USD
3 years ago
Sep 14, 2021
Sell 445 K USD
Wulf John William
Director
- 15342
28.98 USD
3 years ago
Sep 14, 2021
Sell 2.12 M USD
Shaker Benjamin
Chief Markets Officer
- 73018
28.98 USD
3 years ago
Sep 14, 2021
Sell 2.9 M USD
Sell Steven
CEO & President
- 100000
28.98 USD
3 years ago
Sep 14, 2021
Sell 4.53 M USD
Mansukani Sharad
Director
- 156250
28.98 USD
3 years ago
Sep 14, 2021
Sell 333 K USD
Kornitzer Benjamin
Chief Med. & Quality Officer
- 11475
28.98 USD
3 years ago
Sep 14, 2021
Sell 1.7 M USD
Halkias Theodore
Chief Business Officer
- 58553
28.98 USD
3 years ago
Sep 14, 2021
Sell 2.9 M USD
Halkias Theodore
Chief Business Officer
- 100000
28.98 USD
3 years ago
Sep 14, 2021
Sell 1.78 M USD
Dombro Lisa
Exper. & Innovation Officer
- 61543
28.98 USD
3 years ago
Sep 14, 2021
Sell 3.51 M USD
Desai Veeral
Chief Strategy & Dev. Officer
- 121001
28.98 USD
3 years ago
Sep 14, 2021
Sell 519 M USD
CD&R Investment Associates IX, Ltd.
10 percent owner
- 17904257
28.98 USD
3 years ago
Apr 19, 2021
Bought 499 K USD
Richards Clay
Director
+ 21700
23 USD
3 years ago
Apr 19, 2021
Bought 115 K USD
Gourdine Michelle A
Director
+ 5000
23 USD
13 years ago
Nov 18, 2011
Sell 82.8 K USD
RUBRIGHT JAMES A
Director
- 2011
41.15 USD
13 years ago
Nov 18, 2011
Sell 6.1 K USD
RUBRIGHT JAMES A
Director
- 148
41.2 USD
13 years ago
Nov 18, 2011
Sell 4.12 K USD
RUBRIGHT JAMES A
Director
- 100
41.19 USD
13 years ago
Nov 18, 2011
Sell 8.24 K USD
RUBRIGHT JAMES A
Director
- 200
41.18 USD
13 years ago
Nov 18, 2011
Sell 13.6 K USD
RUBRIGHT JAMES A
Director
- 331
41.17 USD
13 years ago
Nov 18, 2011
Sell 148 K USD
RUBRIGHT JAMES A
Director
- 3600
41.16 USD
13 years ago
Nov 18, 2011
Sell 26 K USD
RUBRIGHT JAMES A
Director
- 631
41.16 USD
13 years ago
Nov 18, 2011
Sell 6.26 K USD
RUBRIGHT JAMES A
Director
- 152
41.2 USD
7. News
New Strong Sell Stocks for November 13th AOS, AGL and ABG have been added to the Zacks Rank #5 (Strong Sell) List on November 13, 2024. zacks.com - 3 days ago
Agilon Health price target lowered to $2 from $5 at Barclays Barclays lowered the firm's price target on Agilon Health to $2 from $5 and keeps an Underweight rating on the shares. The company's Q3 results underscore the lack of visibility into real-time trends and limited ability to take control of negative developments, the analyst tells investors in a research note. https://thefly.com - 5 days ago
agilon health, inc. (AGL) Q3 2024 Earnings Call Transcript agilon health, inc. (NYSE:AGL ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Leland Thomas - Senior Manager-Investor Relations Steven Sell - Chief Executive Officer Jeffrey Schwaneke - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Adam Ron - Bank of America George Hill - Deutsche Bank Sameer Patel - Evercore Ryan Langston - TD Cowen Stephen Baxter - Wells Fargo Andrew Mok - Barclays Jack Slevin - Jefferies Michael Ha - Baird Thomas Keller - RBC Daniel Grosslight - Citi Operator Good afternoon and thank you for joining the agilon health Third Quarter 2024 Earnings Conference Call. seekingalpha.com - 6 days ago
agilon health Plunges On A Poor Prognosis (Rating Downgrade) I initially rated agilon health, inc. as a “hold” due to its volatile financial results and uncertain future, but recent developments necessitate a downgrade to 'sell'. The company's stock plummeted 60.1% since my last article, driven by disappointing Q3 results and reduced guidance, despite revenue growth. Rising medical costs and expansion expenses have severely impacted profitability, with a significant increase in net loss and negative EBITDA. seekingalpha.com - 1 week ago
Here's What Key Metrics Tell Us About Agilon (AGL) Q3 Earnings Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 1 week ago
Agilon Health (AGL) Reports Q3 Loss, Lags Revenue Estimates Agilon Health (AGL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.06 per share a year ago. zacks.com - 1 week ago
agilon health to Participate at 2024 Wolfe Research Healthcare Conference AUSTIN, Texas--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will participate in the 2024 Wolfe Research Healthcare Conference including a fireside chat presentation on Tuesday, November 19, at 2:20 PM Eastern Time. A simultaneous webcast for the event can be accessed by visiting the “Events & Presentations” section of agilon's Investor Relations website at https://investors.agilonhe. businesswire.com - 1 week ago
AGILON ALERT: Bragar Eagel & Squire, P.C. is Investigating Agilon Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE: AGL) on behalf of long-term stockholders following a class action complaint that was filed against Agilon on March 19, 2024 with Class Period (1) Agilon common stock purchases traceable to the April 2021 initial public offering of Agilon stock; (2) pursuant, or traceable, or both, to materials issued in connection with the Company's secondary public offering that occurred on or about May 16, 2023; and/or (3) common stock between April 15, 2021 and February 27, 2024. Our investigation concerns whether the board of directors of Agilon have breached their fiduciary duties to the company. globenewswire.com - 2 weeks ago
agilon health Sets Date to Report Third Quarter 2024 Financial Results AUSTIN, Texas--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 7, 2024, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international. businesswire.com - 1 month ago
agilon health: Interesting Business Model, But Volatile And Uncertain agilon hagilon healthealth shares dropped significantly after disappointing financial results, down 11.9% in two days. The company's revenue surged 38.7% year over year, but its net loss nearly doubled, and guidance for 2024 is mixed. Concerns include declining cash reserves, potential for further dilution, and uncertainty regarding share valuation. seekingalpha.com - 3 months ago
AGL Energy Limited (AGLNF) Q4 2024 Earnings Call Transcript AGL Energy Limited (OTCPK:AGLNF) Q4 2024 Earnings Conference Call August 13, 2024 9:00 PM ET Company Participants Damien Nicks - Managing Director and Chief Executive Officer Gary Brown - Chief Financial Officer Markus Brokhof - Chief Operating Officer Jo Egan - Chief Customer Officer Conference Call Participants Tom Allen - UBS Anthony Moulder - Jefferies Dale Koenders - Barrenjoey Reinhardt van der Walt - Bank of America Merrill Lynch Mark Busuttil - JPMorgan Ian Myles - Macquarie Gordon Ramsay - RBC Capital Markets Rob Koh - Morgan Stanley Nik Burns - Jarden Australia Henry Meyer - Goldman Sachs Australia Operator Thank you for standing by and welcome to the AGL Energy Full-Year Results Briefing Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 3 months ago
AGILON ALERT: Bragar Eagel & Squire, P.C. is Investigating Agilon Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE: AGL) on behalf of long-term stockholders following a class action complaint that was filed against Agilon on March 19, 2024 with Class Period (1) Agilon common stock purchases traceable to the April 2021 initial public offering of Agilon stock; (2) pursuant, or traceable, or both, to materials issued in connection with the Company's secondary public offering that occurred on or about May 16, 2023; and/or (3) common stock between April 15, 2021 and February 27, 2024. Our investigation concerns whether the board of directors of Agilon have breached their fiduciary duties to the company. globenewswire.com - 3 months ago
8. Profile Summary

agilon health, inc. AGL

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 651 M
Dividend Yield 0.00%
Description agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
Contact 6210 East US Highway 290, Austin, TX, 78723 https://agilonhealth.com
IPO Date April 15, 2021
Employees 1117
Officers Ms. Denise Zamore Chief Legal Officer & Secretary Mr. Bill Farry Chief of Technology Innovation Mr. Timothy Gertsch Vice President, Controller & Chief Accounting Officer Leland Thomas Senior Manager of Investor Relations Mr. Steven Jackson Sell President, Chief Executive Officer & Director Ms. Claire Mulhearn Chief Communications & Public Affairs Officer Mr. Mat Varghese Chief People Officer Mr. Jeffrey Alan Schwaneke CPA Executive Vice President & Chief Financial Officer Mr. Benjamin Shaker Chief Markets Officer Mr. Girish Venkatachaliah Chief Technology Officer